Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.49 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MASP2 | O00187 | 3/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23273781 | 1.00 | GRIK1 (0.49) | GRIK1ARG1HRH3MASP2SLC2A1 | |
| SCHEMBL16967365 | 1.00 | GRIK1 (0.49) | GRIK1ARG1HRH3MASP2SLC2A1 | |
| SCHEMBL16967363 | 1.00 | GRIK1 (0.49) | GRIK1ARG1HRH3MASP2SLC2A1 | |
| SCHEMBL16967369 | 1.00 | GRIK1 (0.49) | GRIK1ARG1HRH3MASP2SLC2A1 | |
| Hydrochloric Acid SCHEMBL25363248 | 0.99 | GRIK1 (0.50) | GRIK1ARG1HRH3MASP2SLC2A1 | |
| SCHEMBL30323700 | 0.88 | HRH3 (0.41) | GRIK1HRH3MASP2SLC2A1CCR5 | |
| SCHEMBL23118028 | 0.86 | GRIK1 (0.49) | GRIK1ARG1HRH3MASP2F2 | |
| SCHEMBL21429709 | 0.85 | CYP3A4 (0.43) | HRH3MASP2CCR5F2 | |
| SCHEMBL21429712 | 0.85 | CYP3A4 (0.43) | HRH3MASP2CCR5F2 | |
| SCHEMBL11247986 | 0.84 | F2 (0.51) | GRIK1HRH3MASP2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558246-B1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1558246-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132801-A1 | Therapeutic proline derivatives | RAWSON DAVID JAMES (GB) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132801-A1 | Therapeutic proline derivatives | PRRC2C, SLC6A7, FAAH | GRIK1 449/4885ARG1 1752/4885HRH3 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.